Congestive Heart Failure Treatment Market Predicted Growth At 4.47% CAGR To 35.5 Billion USD By 2032 Gilead Sciences The Global Congestive Heart Failure Treatment market is witnessing significant ...

In a report released yesterday, Matthew Biegler from Oppenheimer reiterated a Buy rating on Nurix Therapeutics (NRIX – Research Report), with a ...

Cell Therapy Regenerative medicine Market. The Cell Therapy Regenerative Medicine market is poised for significant growth, driven by advancements in techno ...

In the most recent trading session, Gilead Sciences (GILD) closed at $93.85, indicating a -1.57% shift from the previous trading day.

The stock's fall snapped a two-day winning streak.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...

The leading Crohn's Disease companies such as Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a ...

This was the stock's second consecutive day of gains.

Gilead Sciences GILD +2.54% Get Free Report has outperformed the market over the past 20 years by 4.74% on an annualized ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

Janney Montgomery Scott LLC lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 47.0% ...